Cutting Edge Science for the Skin
Claradele Pharmaceuticals (Claradele) is an early-stage biotechnology company whose primary focus is to develop effective and non-toxic therapeutics for cancer. The company was founded in 2020 to accelerate the development of a novel, small molecule drug class with both cytotoxic and immunostimulatory activity. Our current development efforts center on the production of melanoma therapeutics aimed at the US and European markets. The company was founded by our academic inventor who has more than 20 years of experience in the cancer research field. Working in concert with our strong consortium of academic scientists, Claradele seeks to supply innovative approaches for treating cancer.
Our technology, 15dPMJ2 (US Patent #9,328,060), targets tumor cells while having minimal impact on non-tumor tissues, an action that reduces the occurrence of side effects. The targeted tumor cells undergo a form of apoptosis that causes the tumor cell to be eliminated by immune cells that remember the tumor cell to prevent the cancer from returning. These actions along with the relatively low cost of production will result in longer survival and a better quality of life for a significant population of melanoma patients. Moreover, since the technology targets a common pathway in cancer, it may also be useful for other malignancies including colon and lung cancer.
15dPMJ2, has demonstrated chemotherapeutic activity in different models of cancer. Our preclinical trials have shown that it increased the tumor infiltration immune cell types that attack cancer and it reduced tumor growth by 76%. 15dPMJ2 is unique among immunostimulants in that it activates immune responses towards tumorigenic compared to non-tumorigenic melanocytes suggesting that it will cause minimal toxicity. The tumor selectivity of 15dPMJ2 was dependent on its ability to induce cytotoxic endoplasmic reticulum (ER) stress. 15dPMJ2 will provide patient benefit by generating tumor-directed immunostimulatory activity with a favorable safety profile at a more affordable cost than current melanoma therapeutics.
B16F10 cells were injected into the subcutaneous space of C57BL/6 mice to determine the effect of 15dPMJ2 on tumor survival.
Tumorigenic (B16F10) and non-tumorigenic (Melan-A) melanocytes were treated with different concentrations of 15dPMJ2
. B16F10 cells that were treated with cisplatin (CIS), OXA, 15dPMJ2 or vehicle were implanted in the subcutaneous flank of C57BL/6 mice.